Young girl

Global partnerships

We know that many of the best ideas can come from outside of GSK, and collaborating with other companies, organizations, nonprofits/NGOs, and academics is a fundamental part of our business strategy.

We are committed to working with partners to deliver innovative new medicines, vaccines, and consumer healthcare products, and to develop new ways of working.

GSK/McLaren Partnership

In September 2011, GSK and the McLaren Group joined forces to share knowledge and expertise with the aim of improving our business performance and driving a more dynamic business culture. 

Bringing together two science-led companies, the unique partnership looks to identify opportunities to align the high-tech innovation demonstrated by McLaren, particularly in Formula 1, with our strengths in manufacturing, R&D, and nutritional research.

Learn more about our McLaren parntership

GSK/Save the Children Partnership

The partnership goes well beyond the traditional charity and corporate fundraising model. It will touch many areas of our business, in particular using our R&D capabilities to help save children’s lives.

The GSK and Save the Children partnership will focus in particular on:

  • developing child-friendly medicines to reduce child mortality and new-born deaths
  • widening vaccination coverage to reduce the number of child deaths in the hardest to reach communities
  • researching new affordable nutritional products to help alleviate malnutrition in children
  • increasing investment in the training, reach and scope of health workers in the poorest communities to help reduce child mortality

In the US, GSK is working with Save the Children to help ensure school children living in rural poverty have access to regular physical activity and healthy food choices and also to provide for the needs of children affected by emergencies such as natural disasters.

Learn more about our Save the Children partnership

Bioelectronics R&D

The functions and organ systems of our body are, to a significant extent, controlled by electrical signals that travel along the nerves. Bioelectronic medicines will aim to control biological processes and treat disease by modulating these electrical impulses.

They will be minaturised devices that connect to specific groups of neurons or their nerve fibres and modulate the electrical signalling patterns, to restore the healthy states of targeted organs and functions.

We believe bioelectronic medicines could allow us to address some diseases that have so far been untreatable, and others with greater precision and fewer side effects than with conventional molecular medicines.

Learn more about our Bioelectronics R&D